The Cooper Companies, Inc.COO
NasdaqGS•Healthcare•Medical Instruments & Supplies
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
as of April 2026
Are revenues and earnings expanding?
$4.23B in TTM revenue grew 6.1% YoY, reaching $1.08B last quarter. TTM EBITDA of $882.60M on operating income of $-31.00M shows growth is flowing through. Net income of $235.80M TTM confirms the company is converting revenue into profit. Revenue is growing at a healthy pace — a signal to hold.
Is revenue turning into profit effectively?
Op. margin of -2.9% is down 21.3% YoY — costs are rising relative to revenue. Net margin at -7.2% and gross margin of 68.0%. ROE of 2.9% shows the company generates solid returns on shareholder equity.
Is the stock cheap or expensive?
At 53.8x P/E, the stock trades at a premium — the market expects above-average growth. P/S of 3.0x and P/B of 1.5x provide additional context. Assess whether the current multiple is justified by the company's growth and profitability trajectory.
Is the company financially stable?
With $12.48B in assets and $1.86B in long-term debt, the D/E of 0.2 shows a conservative capital structure — the company has a strong financial cushion to weather downturns.
Is the business self-funding?
FCF of $96.40M on $182.80M in operating cash flow. The FCF / Net Income ratio of 0.4x indicates partial cash conversion — earnings quality needs attention. Cash reserves of $138.80M provide financial flexibility. Shares outstanding declined 2.5% YoY — buybacks are returning capital to shareholders.
Competitive analysis based on 64 quarters of fundamental data
Operating margins are under pressure, averaging 15.5%. The business may lack pricing power or face rising costs.'
ROE is positive at ~4.6% on average, adequate but below the threshold typically associated with wide moats.
Free cash flow is consistently positive and growing — a hallmark of a capital-light business that can self-fund growth.
TTM revenue has grown consistently (7 of 7 quarters up), with ~11.2% growth over the period. Strong demand durability.
Data-driven red flags and warnings across 64 quarters
Operating margins dropped 37.3% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.
FCF covers net income by 0.9x on average — earnings are well-supported by cash generation.
D/E ratio is 0.2 — conservative capital structure with low financial risk.
Revenue is stable or growing over recent quarters — demand appears durable.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Shares decreased 2.1% — net buybacks are reducing shares outstanding and boosting per-share value.